SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Pharmos (PARS)
An SI Board Since October 1998
Posts SubjectMarks Bans Symbol
1386 42 0 PARS
Emcee:  Dr. John M. de Castro Type:  Unmoderated
Introduction Market Data Compact
Pharmos (PARS) is a biotech company that is doing the unimaginable. They are on the brink of profitability. They have two products that are FDA approved, Lotemax and Alrex, which are for the treatment of ocular inflammation and allergy. PARS has a marketing agreement with Bausch & Lomb Pharmaceuticals for sale of Lotemax and Alrex in the US, Canada, and Europe. They are already showing signs of becoming cash cows for the company. In addition, PARS has an interesting pipeline. The Company has another ophthalmic product about to enter Phase III clinical trials, My interest was drawn to PARS because of their Phase II trial results of HU-211 for traumatic head injury. HU-211 is a non-competitive NMDA antagonist that the Phase II results suggest is effective for neuroprotection. The results were excellent and suggest that HU-211 may become a front line treatment for traumatic head injury. There is an active and informative Pharmos thread in the "$5 and Under" category.

Subject 10176

However, PARS is a biotechnology company and discussion of this stock belongs in the biotech category. So, I am opening this thread.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1386Pharmos Corporation Engages Burrill & Company for Business Development Initinigel bates-5/19/2006
1385I finally took a loss at the end of the year and sold my shares. Stock was up tMichael Casey-1/21/2006
1384I am watching, but not investing. Management is too self-serving, though this opTony van Werkhooven-1/9/2006
1383No response on the board, cant be a good thing if nobody is watching this stock.thelaw-1/9/2006
1382I have been an investor pf PARS for years now and still have not seen anything gthelaw-1/6/2006
1381Wholeheartedly agreed upon. Midasmidastouch017-4/16/2005
1380Association with Haim Aviv causes poison ivy; he should be scrubbing toilets in LLLefty-4/13/2005
1379Predix gears up for Nasdaq IPO 13.4.2005 / 09:02 Oded Hermoni After many disamidastouch017-4/13/2005
1378Pharmos' Disappointing Brain-Injury Treatment Andy Stone, 12.20.04, 7:25 PMmikehunt2-12/29/2004
1377Harry, even if there was foul play hindsight is always 20/20. I have only myselfrjk01-12/27/2004
1376I have not forgotten that I said that Aviv had the right to not have too much ofNeuroInvestment-12/24/2004
1375Harry, so what I hear you saying is…: <b>The CEO has to go!</b> &rjk01-12/24/2004
1374They reported only the first and most crucial analyses as they were completed. TNeuroInvestment-12/23/2004
1373Harry, any update on current situation? Did anyone have a chance to review the rjk01-12/23/2004
1372Anat Biegon used to be Pharmos' CSO--very bright. The delay to administratioNeuroInvestment-12/21/2004
1371Harry, I wonder if timing of dosing might not be very critical? I don't knoBiomaven-12/21/2004
1370Thanks neuro - Upon further thought, I came up with a broader list of possible Clarksterh-12/21/2004
1369I asked Gad Riesenfeld (maybe there was a breakdown in our English communicationNeuroInvestment-12/20/2004
1368Globes" was first to report that Phase III clinical trials of dexanabinol hrjk01-12/20/2004
1367Thanks Neuro - <i>1) The dex used in this trial was not from the new manufClarksterh-12/20/2004
1366The way I read the CC, Aviv own words were that they are done with this one. Therjk01-12/20/2004
1365As part of the post-mortem for dex's TBI trial: 1) The dex used in this triaNeuroInvestment-12/20/2004
1364Harry and all..I'm so disappointed with you..I was rooting for this moleculezeta1961-12/20/2004
1363from Globes; Pharmos Phase III: Dexanabinol not effective against TBI CEO Dr. Hrjk01-12/20/2004
1362Although I am no longer interested in Pharmos as an investment, I am interested Clarksterh-12/20/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News